Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Study Details
Study Description
Brief Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have refractory advanced solid tumors or lymphoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
OBJECTIVES:
-
Determine the maximum tolerated dose (MTD) of monoclonal antibody anti-alpha V beta 3 integrin (MEDI 522) in patients with refractory advanced solid tumors or lymphoma.
-
Determine the safety and tolerability of this drug in these patients.
-
Demonstrate significant binding of this drug to its molecular target in vivo in these patients.
-
Determine the effects of this drug on angiogenesis in these patients.
-
Determine antitumor activity of this drug by measuring tumor size and glucose uptake in these patients.
-
Determine the pharmacokinetics of this drug in these patients.
-
Determine a recommended phase II dose of this drug based on either the MTD or the optimal biologic response in these patients.
OUTLINE: This is a dose-escalation study.
Patients receive monoclonal antibody anti-alpha V beta 3 integrin (Medi 522) IV over 30 minutes weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 6 patients receive escalating doses of Medi 522 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: Approximately 6-30 patients will be accrued for this study.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically or cytologically confirmed solid tumor or lymphoma that is refractory to currently available standard therapies or for which there are no curative therapies
-
No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- More than 12 weeks
Hematopoietic
-
WBC at least 3,000/mm^3
-
Absolute neutrophil count at least 1,500/mm^3
-
Platelet count at least 100,000/mm^3
-
No prior bleeding disorder
Hepatic
-
Bilirubin normal
-
AST/ALT no greater than 2.5 times upper limit of normal
-
INR/PTT normal
Renal
-
Creatinine normal OR
-
Creatinine clearance at least 60 mL/min
Cardiovascular
-
No symptomatic congestive heart failure
-
No unstable angina pectoris
-
No cardiac arrhythmia
Other
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective contraception during and for 6 months after study participation
-
HIV negative
-
T4 or thyroid stimulating hormone normal
-
No thyroid disease
-
No prior allergic reactions attributed to compounds of similar chemical or biologic composition to study drug (e.g., rituximab or immunoglobulin G)
-
No ongoing or active infection
-
No other uncontrolled concurrent illness that would preclude study participation
-
No psychiatric illness or social situation that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
Endocrine therapy
- Not specified
Radiotherapy
- More than 4 weeks since prior radiotherapy and recovered
Surgery
- More than 4 weeks since prior surgery
Other
-
No other concurrent investigational agents
-
No other concurrent anticancer agents or therapies (commercial or investigational)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin | United States | 53792 |
Sponsors and Collaborators
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
Investigators
- Study Chair: Douglas McNeel, MD, PhD, University of Wisconsin, Madison
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000257810
- P30CA014520
- WCCC-CO-01905
- NCI-5497